Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Halozyme Therapeutics' (HALO) Price Target Raised to $21 at JMP
June 4, 2015 8:23 AM EDTJMP Securities maintained a Market Outperform rating on Halozyme Therapeutics (NASDAQ: HALO) and raised its price target to $21.00 (from $17.00).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $19.57 yesterday.
... MoreHalozyme Therapeutics (HALO) PT Lifted to $21 at Piper Jaffray on AbbVie Deal
June 3, 2015 1:23 PM EDTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) after the company announced an Enhanze partnership with yet another large biopharma player, AbbVie.
Duncan commented, ". We're not too surprised given management's... More
Halozyme Therapeutics (HALO), AbbVie (ABBV) Enter Collaboration for ENHANZE Combinations
June 3, 2015 8:31 AM EDTHalozyme Therapeutics (NASDAQ: HALO) announced a global collaboration and license agreement with AbbVie (NYSE: ABBV) to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.
Under the terms of the agreement, Halozyme will receive an initial $23 million... More
